Gastroenterology Research and Practice / 2022 / Article / Tab 1 / Research Article
Transanal versus Laparoscopic Total Mesorectal Excision in Male Patients with Low Tumor Location after Neoadjuvant Therapy: A Propensity Score-Matched Cohort Study Table 1 Demographic and clinical data before and after propensity score matching.
Characteristics Before propensity score matching After propensity score matching taTME ( ) laTME ( ) taTME ( ) laTME ( ) Age, (range) (23-78) (20-80)0.08 (23-78) (26-79)0.80 BMI, (range) (17.1-37.6) (15.9-34.2)0.10 (17.2-32.3) (16.9-34.3)0.85 Tumor location, (range) (1.0-5.0) (1.4-5.0)<0.001 (2.0-5.0) (1.4-5.0)0.20 Tumor size (cm), (range) (0.3-6.6) (0-8.0)0.07 (0.3-6.6) (0-8.0)0.20 Preoperative intestinal obstruction, (%) <0.001 — None 112 (100%) 199 (93.4%) 106 (100%) 106 (100%) Incomplete 0 (0%) 14 (6.6%) — — History of past abdominal surgery, (%) 0.68 1.00 Without 105 (93.8%) 202 (94.8%) 101 (95.3%) 102 (96.2%) With 7 (6.3%) 11 (5.2%) 5 (4.7%) 4 (3.8%) cT, (%) 0.23 0.53 T0 0 (0%) 1 (0.5%) — — T1 1 (0.9%) 1 (0.5%) 1 (0.9%) 0 (0%) T2 12 (10.7%) 41 (19.2%) 12 (11.3%) 18 (17.0%) T3 90 (80.4%) 156 (73.2%) 86 (81.1%) 82 (77.4%) T4 9 (8%) 14 (6.6%) 7 (6.6%) 6 (5.7%) cN, (%) 0.09 0.63 N0 63 (56.3%) 145 (68.1%) 60 (56.6%) 66 (62.3%) N1 33 (29.5%) 47 (22.1%) 31 (29.2%) 25 (23.6%) N2 16 (14.3%) 21 (9.9%) 15 (14.2%) 15 (14.2%) cM, (%) 0.24 1.00 M0 108 (96.4%) 210 (98.6%) 102 (96.2%) 103 (97.2%) M1 4 (3.6%) 3 (1.4%) 4 (3.8%) 3 (2.8%) Type of neoadjuvant therapy regimen, (%) <0.001 0.47 Only chemotherapy 77 (68.8%) 89 (41.8%) 71 (67.0%) 66 (62.3%) Radiochemotheraoy 35 (31.3%) 121 (56.8%) 35 (33.0%) 40 (37.7%) Only radiotherapy 0(0%) 3(1.4%) — —